Recro Pharma presents results from meloxicam IV study at PGA72
Recro Pharma announced a poster presentation highlighting intravenous, or IV, meloxicam's effect on platelet function at the PostGraduate Assembly in Anesthesiology, or PGA72. The poster describes results from an ex vivo study assessing the effects of various concentrations of IV meloxicam on platelet function compared to ketorolac and an untreated control. The 5mcg/mL concentration of IV meloxicam in this study corresponds to the maximum plasma levels following a 30mg dose in the clinical setting. Similarly, the 5mcg/mL concentration of ketorolac in this study corresponds to a 30mg and the 2.5mcg/mL dose corresponds to the 15mg dose in the clinical setting. In this study, blood samples provided by healthy volunteers were analyzed to determine closure time, or CT, following the addition of IV meloxicam and ketorolac at the previously mentioned concentrations to the blood plasma samples. The researchers conducted the analyses using a platelet function analyzer, a standard of care for platelet function testing, or CEPI, and two different reagents, collagen with epinephrine and collagen with adenosine diphosphate, or CADP. In the CEPI reagent analysis, a significant treatment effect was observed for changes in CT. No significant difference was observed in CT for the IV meloxicam treated samples versus the untreated control at any of the evaluated concentrations. When compared to untreated control, the ketorolac treated sample CT values were significantly prolonged in both the 2.5mcg/mL and the 5mcg/mL concentrations. All IV meloxicam concentration levels had a significantly shorter CT compared to the 2.5mcg/mL ketorolac concentration. All IV meloxicam concentration levels had numerically shorter CTs compared to the 5mcg/mL ketorolac concentration, though only the 10mcg/mL IV meloxicam concentration reached statistical significance. In the CADP reagent analysis, neither IV meloxicam nor ketorolac demonstrated a significant change in CT versus untreated control.